RxDoctor Payments Data

Basel Brikho, MD

Internal Medicine · Lathrup Village, MINPI 1285721514

Payments from drug & device makers

$2,039in general payments, 2019–2025

Across 85 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$428
  • Novo Nordisk$405
  • Amgen$155
  • Agios Pharmaceuticals, Inc.$137
  • Lilly USA, LLC$132
  • Johnson & Johnson$124
  • plus $658 from 14 others

What the payments were for

  • Food & beverage$2,02299%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,039 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$175,843
Medicare patients
245
Services billed
2,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate162$146,338
JardianceEmpagliflozin163$137,098
EliquisApixaban196$130,317
FarxigaDapagliflozin Propanediol106$85,721
LinzessLinaclotide137$75,915
ProliaDenosumab38$64,444
TradjentaLinagliptin110$62,659
MyrbetriqMirabegron48$30,582
XareltoRivaroxaban38$28,636
TrulicityDulaglutide19$27,817
Breo ElliptaFluticasone/Vilanterol51$20,258
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$17,690
Diclofenac Sodium339$9,957
Fluticasone-SalmeterolFluticasone Propion/Salmeterol54$9,828
Atorvastatin Calcium1,487$9,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$130,317196 claims
AstraZenecaFarxiga, Brilinta, Symbicort$428$94,508132 claims
AbbVieLinzess, Synthroid$69$79,628165 claims
AmgenProlia$155$64,44438 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$23$43,02191 claims
Johnson & JohnsonXarelto$124$28,63638 claims
Lilly USA, LLCTrulicity$132$27,81719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lathrup Village

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →